ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation - Wu, Youqian; Zhang, Chao; Liu, Xiaolan; He, Zhengfu; Shan, Bing; Zeng, Qingxin; Zhao, Qingwei; Zhu, Huaying; Liao, Hongwei; Cen, Xufeng; Xu, Xiaoyan; Zhang, Mengmeng; et al. (Nature communications, 2021)
Keywords: 13; 13/1; 13/31; 13/51; 13/89; 13/95; 49; 631/337; 631/80; 64; 64/60; 82/83; Animals; B7-H1 Antigen - chemistry; B7-H1 Antigen - metabolism; Cancer; Cell activation; CTLA-4 Antigen - antagonists & inhibitors; CTLA-4 protein; Cytotoxicity; Degradation; Drug screening; Drug Screening Assays, Antitumor; Epidermal growth factor receptors; ErbB Receptors - antagonists & inhibitors; Female; Glycogen Synthase Kinase 3 - metabolism; HEK293 Cells; High-Throughput Screening Assays; Humanities and Social Sciences; Humans; Immunity; Immunotherapy; Immunotherapy - methods; Lymphocytes; Lymphocytes T; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; multidisciplinary; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - therapy; PD-L1 protein; Phosphorylation; Proteasome Endopeptidase Complex - metabolism; Proteasomes; Proteolysis; Science; Science (multidisciplinary); Signal Transduction; Signaling; T-Lymphocytes, Cytotoxic - drug effects; T-Lymphocytes, Cytotoxic - immunology; Therapeutic targets; Tumor Escape - physiology; Tumors; U937 Cells; Ubiquitin; Ubiquitin-protein ligase; Ubiquitin-Protein Ligases - metabolism; Ubiquitination; Ubiquitination - drug effects